Polyrizon Announces Successful NASARIX™ Biocompatibility Program Results

Key Highlights

• Polyrizon announced successful results for its NASARIX™ Allergy Blocker nasal spray biocompatibility program.
• All required biological safety tests met predetermined acceptance criteria.
• The program evaluated cytotoxicity, sensitization, irritation, material-mediated pyrogenicity, and acute systemic toxicity.
• Long-term systemic toxicity was assessed through a toxicological risk assessment per ISO 10993-17.
• The evaluation was conducted in accordance with ISO 10993 series, FDA guidance, and European regulatory requirements.
• Successful completion is a significant milestone supporting advancement towards first-in-human clinical trials.